Mustang Bio, Inc.
MBIONASDAQHealthcareBiotechnology
Previous close
$0.5787
+$0.0111 · +1.96%
MBIO company overview
Regular session · ET · Market data may be delayed.
GoAI snapshot
AI-powered factor overview
GoAI score
Sell
Trim exposure — unfavorable risk-reward
Valuation
58
Fair Value
Momentum
29
Weakening
Sentiment
41
Mixed
Risk resilience
16
Extreme Risk
Full GoAI research
Thesis, catalysts, evidence, and risk analysis.
AI-generated, informational only, and not investment advice.
Company profile
Company websiteMustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134. It has a license agreement with city of hope national medical center and nationwide children’s hospital. Mustang Bio, Inc. was incorporated in 2015 and is headquartered in Waltham, Massachusetts.
- Industry
- Biotechnology
- Sector
- Healthcare
- Headquarters
- US
- CEO
- Manuel Litchman
- Listed since
- Aug 22, 2017
- Employees
- 4
Market position
Day range
Current $0.5787
52-week range
Current $0.5787
- Open
- $0.5769
- Previous close
- $0.5676
- Volume
- 6.37K
- 0.06× average
- Average volume
- 102.17K
- Average daily volume
- Market cap
- 4.39M USD
- Beta
- 2.05
- Market reference 1
- 50-day average
- $0.6426
- -9.94% below average
- 200-day average
- $0.8577
- -32.52% below average
Financials
Financial snapshot
Latest / TTMValuation & yield
- Enterprise value
- -12.45M USD
- P/E (TTM)
- -1.29×
- P/B (TTM)
- 0.52×
- P/S (TTM)
- 0×
- EV / EBITDA
- 6.62×
- Earnings yield
- -39.90%
- Free cash flow yield
- -109.33%
- Dividend yield
- 0.00%
Profitability & efficiency
- Gross margin
- 0.00%
- Operating margin
- 0.00%
- Net margin
- 0.00%
- Return on equity
- -20.16%
- Return on assets
- -10.92%
- Return on invested capital
- -25.13%
Financial health
- Debt / equity
- 0×
- Current ratio
- 2.22×
- Altman Z-score
- -35.65
- Piotroski F-score
- 1 of 9
Earnings
- EPS beat rate
- 63%
- 5 beats, 3 misses, 0 met estimates
- Average EPS surprise
- -347.48%
- 8 comparable reports
- Latest EPS result
- -0.16
- Estimate -140 · Beat by 99.89%
EPS: actual versus estimate
Recent quarterly results
Analyst ratings
Third-party consensus; not a GoAI recommendation.
Rating distribution
7 ratingsMBIO peers
ETFs holding MBIO
Funds reporting this stock among their holdings, ordered by reported position size.
Continue in GoAI
Research MBIOresearch.disclaimer